Business Wire

HKSTP

13.1.2021 12:32:31 CET | Business Wire | Press release

Share
City I&T Grand Challenge Invites Innovative Solutions From the Community for Smart Living Under New Normal

Organised by the Innovation and Technology Commission together with the Hong Kong Science and Technology Parks Corporation, the first City I&T Grand Challenge was launched. In light of the new normal under the epidemic, the theme of the competition this year is “Innovating for Hong Kong’s New Normal” and invites all sectors of the community to put forward innovation and technology (I&T) solutions focusing on two issues, namely environmental sustainability and social connectivity, to tackle problems facing the city and people in their daily lives. A series of workshops and other activities will also be held to create an I&T atmosphere in the whole community.

In his video speech for the launch of the event, the Financial Secretary, Mr Paul Chan, said that the Government has allocated over $100 billion in recent years for I&T infrastructure and development. It has provided full support for nurturing I&T talents and fostering an I&T ecosystem. It is committed to improving the entire I&T industry chain from research and development (R&D) to production and marketing, enabling local I&T talents and enterprises to excel. The COVID-19 epidemic has led people to change their old lifestyles and to think about how to solve problems with technology. He believes that the City I&T Grand Challenge will draw creative ideas from all sectors for developing I&T and smart living proposals to help people live as usual and even in a better way in the new normal during and after the epidemic.

The Secretary for Innovation and Technology, Mr Alfred Sit, said in his video address that, in addition to promoting a diversified economy and injecting new impetus into the economy of Hong Kong, an even more important objective for the Government to push forward I&T development is to improve the quality of life, bringing convenience and benefits to members of the public. Describing the City I&T Grand Challenge as an “I&T marathon”, Mr Sit hoped the whole community could take part in and benefit from it. He also hoped that the City I&T Grand Challenge will fuel community-wide enthusiasm for I&T, especially among young people.

Speaking at the media briefing of the competition, the Commissioner for Innovation and Technology, Ms Rebecca Pun, said that, while some business plan competitions put focus on the team members and product development capabilities of a company and its investment prospects, the City I&T Grand Challenge evaluates each proposal based on its originality, uniqueness and effectiveness, application of innovation and technology, as well as social benefits and impact.

Also speaking at the briefing, the Chief Executive Officer of the Hong Kong Science and Technology Parks Corporation, Mr Albert Wong, said that everyone has the potential to be an innovator to shape the future. The City I&T Grand Challenge offers an invaluable opportunity for the public to apply creativity and develop smart solutions catering to the new normal under the epidemic for the benefit of the community.

The City I&T Grand Challenge is open for application from today till 24 April 2021. Target participants range from primary and secondary school students to local and non-local tertiary students, technology enterprises, R&D teams and entrepreneurs. Winners will be awarded a cash prize and a trophy. For the winners of the University and Open categories, they will also have a chance to receive R&D resources and training for refining their I&T solutions for trying at a designated venue such as a government department or a public organisation.

Under each of the focused issues of environmental sustainability and social connectivity, the City I&T Grand Challenge sets up two specific scenarios for participants to select for developing innovative solutions. For “environmental sustainability”, the two scenarios are surrounding disposable plastic tableware and household food waste, which are pressing environmental problems in the new normal. As regards “social connectivity”, the two scenarios are mainly concerned about the physical and social well-being of senior citizens and children under the new normal of social distancing and distant learning.

The website of the City I&T Grand Challenge has been launched for the public to submit applications. A host of workshops, seminars and training activities will also be organised to introduce knowledge on technologies and entrepreneurship as well as topical daily life issues. All are welcome to join. Details are available at the event website (citytechgc.hk ).

*Videos and images are available for download here .

About Hong Kong Science and Technology Parks Corporation

Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.

Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.

Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye